BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 32219730)

  • 1. High-dose
    Kayano D; Wakabayashi H; Nakajima K; Kuroda R; Watanabe S; Inaki A; Toratani A; Akatani N; Yamase T; Kunita Y; Hiromasa T; Takata A; Mori H; Saito S; Araki R; Taki J; Kinuya S
    Ann Nucl Med; 2020 Jun; 34(6):397-406. PubMed ID: 32219730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different outcomes for relapsed versus refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG).
    Zhou MJ; Doral MY; DuBois SG; Villablanca JG; Yanik GA; Matthay KK
    Eur J Cancer; 2015 Nov; 51(16):2465-72. PubMed ID: 26254811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine-131 metaiodobenzylguanidine (131I-mIBG) treatment in relapsed/refractory neuroblastoma.
    Anongpornjossakul Y; Sriwatcharin W; Thamnirat K; Chamroonrat W; Kositwattanarerk A; Utamakul C; Sritara C; Chokesuwattanasakul P; Thokanit NS; Pakakasama S; Anurathapan U; Pongphitcha P; Chotipanich C; Hongeng S
    Nucl Med Commun; 2020 Apr; 41(4):336-343. PubMed ID: 31939898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial.
    Matthay KK; Weiss B; Villablanca JG; Maris JM; Yanik GA; Dubois SG; Stubbs J; Groshen S; Tsao-Wei D; Hawkins R; Jackson H; Goodarzian F; Daldrup-Link H; Panigrahy A; Towbin A; Shimada H; Barrett J; Lafrance N; Babich J
    J Nucl Med; 2012 Jul; 53(7):1155-63. PubMed ID: 22700000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
    Trieu M; DuBois SG; Pon E; Nardo L; Hawkins RA; Marachelian A; Twist CJ; Park JR; Matthay KK
    Pediatr Blood Cancer; 2016 Mar; 63(3):436-42. PubMed ID: 26506090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose
    Wakabayashi H; Kayano D; Inaki A; Araki R; Kuroda R; Ikawa Y; Fujiki T; Akatani N; Yamase T; Watanabe S; Hiromasa T; Kunita Y; Mori H; Saito S; Nishimura R; Wada T; Kinuya S
    Ann Nucl Med; 2020 Nov; 34(11):840-846. PubMed ID: 32862362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of
    Sevrin F; Kolesnikov-Gauthier H; Cougnenc O; Bogart E; Schleiermacher G; Courbon F; Gambart M; Giraudet AL; Corradini N; Badel JN; Rault E; Oudoux A; Deley MCL; Valteau-Couanet D; Defachelles AS
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30615. PubMed ID: 37574821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma.
    Kang TI; Brophy P; Hickeson M; Heyman S; Evans AE; Charron M; Maris JM
    J Pediatr Hematol Oncol; 2003 Oct; 25(10):769-73. PubMed ID: 14528098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
    Matthay KK; Yanik G; Messina J; Quach A; Huberty J; Cheng SC; Veatch J; Goldsby R; Brophy P; Kersun LS; Hawkins RA; Maris JM
    J Clin Oncol; 2007 Mar; 25(9):1054-60. PubMed ID: 17369569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
    Kraal KC; van Dalen EC; Tytgat GA; Van Eck-Smit BL
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010349. PubMed ID: 28429876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
    Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
    Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation exposure to family caregivers and nurses of pediatric neuroblastoma patients receiving 131I-metaiodobenzylguanidine (131I-MIBG) therapy.
    Markelewicz RJ; Lorenzen WA; Shusterman S; Grant FD; Fahey FH; Treves ST
    Clin Nucl Med; 2013 Aug; 38(8):604-7. PubMed ID: 23797228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicity of upfront ¹³¹I-metaiodobenzylguanidine (¹³¹I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis.
    Bleeker G; Schoot RA; Caron HN; de Kraker J; Hoefnagel CA; van Eck BL; Tytgat GA
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1711-7. PubMed ID: 23921531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 131I-metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study.
    Yanik GA; Villablanca JG; Maris JM; Weiss B; Groshen S; Marachelian A; Park JR; Tsao-Wei D; Hawkins R; Shulkin BL; Jackson H; Goodarzian F; Shimada H; Courtier J; Hutchinson R; Haas-Koga D; Hasenauer CB; Czarnecki S; Katzenstein HM; Matthay KK
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):673-81. PubMed ID: 25639769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma.
    George SL; Falzone N; Chittenden S; Kirk SJ; Lancaster D; Vaidya SJ; Mandeville H; Saran F; Pearson AD; Du Y; Meller ST; Denis-Bacelar AM; Flux GD
    Nucl Med Commun; 2016 May; 37(5):466-72. PubMed ID: 26813989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.
    Kraal KC; Bleeker GM; van Eck-Smit BL; van Eijkelenburg NK; Berthold F; van Noesel MM; Caron HN; Tytgat GA
    Eur J Cancer; 2017 May; 76():188-196. PubMed ID: 28329731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours.
    Monsieurs MA; Thierens HM; Vral A; Brans B; De Ridder L; Dierckx RA
    Nucl Med Commun; 2001 Apr; 22(4):367-74. PubMed ID: 11338046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.
    Willegaignon J; Crema KP; Oliveira NC; Pelissoni RA; Coura-Filho GB; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2018 Aug; 43(8):572-578. PubMed ID: 29916922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
    Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
    J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.